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Gastric cancer is the second cancer causing death worldwide. Both incidence and mortality rates vary according to
geographical regions. The receptor for urokinase plasminogen activator (uPAR) is involved in extracellular matrix degradation
by mediating cell surface associated plasminogen activation, and its presence on gastric cancer cells is linked to micro-
metastasis and poor prognosis. Immunohistochemical analyses of a set of 44 gastric cancer lesions from Costa Rica showed
expression of uPAR in cancer cells in both intestinal subtype (14 of 27) and diffuse subtype (10 of 17). We compared the
expression pattern of uPAR in gastric cancers from a high-risk country (Costa Rica) with a low-risk country (Norway). We found
uPAR on gastric cancer cells in 24 of 44 cases (54%) from Costa Rica and in 13 of 23 cases (56%) from Norway. uPAR was
seen in macrophages and neutrophils in all cases. We also examined the nonneoplastic mucosa and found that uPAR was
more frequently seen in epithelial cells located at the luminal edge of the crypts in cases with Helicobacter pylori infection
than in similar epithelial cells in noninfected mucosa (p 5 0.033; v2 5 4.54). In conclusion, the expression of uPAR in cancer
cells in more than half of the gastric cancer cases suggests that their uPAR-positivity do not contribute to explain the
different mortality rates between the 2 countries, however, the actual prevalence of uPAR-positive cancer cells in the gastric
cancers may still provide prognostic information.
Gastric cancer is the second most common cancer causing
death worldwide after lung cancer and is a ﬁnal result of the
stepwise process initiated by environmental factors including
diet and Helicobacter pylori infection.1–3 In particular,
H. pylori infection is one of the most recognized risk factors
for this malignancy.4–6 Both the incidence and mortality rates
of gastric cancer present substantial variations according to
geographical regions (between and within countries).1 The
factors explaining these variations remain unknown so far
given the complexity and multifactorial nature of the disease.
Costa Rica is one of the countries with highest incidence and
mortality rates for gastric cancer worldwide. In contrast,
most of western European countries present low incidence
and low mortality rates for this malignancy.1,7
Among the key events for cancer development and pro-
gression are neoplastic cell invasion into the adjacent normal
tissue and eventually metastasis. Invasion and metastasis are
facilitated by a number of proteinases capable of degrading
the extracellular matrix (ECM).8,9 Plasmin can degrade major
ECM proteins like ﬁbrin, ﬁbronectin and laminin and in
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addition can activate other matrix degrading proteinases.
Plasmin is formed on cell surfaces after proteolytic cleavage
of its zymogen plaminogen by urokinase-type plasminogen
activator (uPA).10 uPA mediates plasminogen activation after
binding with high afﬁnity to its speciﬁc receptor (uPAR), a
3-domain GPI-linked cell surface protein.11 uPAR is predom-
inantly seen on inﬂammatory cells and to a lesser extent on
cancer cells in areas of cancer invasion in several types of
cancer including gastric, colon, breast and oral cancer.12–17
In gastric cancer lesions, uPAR expression has been
observed in macrophages, endothelial cells and cancer cells
located at the invasive front of the tumors.15,18,19 Increased
expression of uPAR antigen or mRNA in tissue extracts and
blood from patients with gastric cancer have been associated
with some clinico-pathological aspects of the disease includ-
ing poor prognosis.18–26 Interestingly, studies in bone marrow
aspirates from curatively resected patients with gastric cancer
show that those cases with uPAR-positive cancer cells disse-
minated into the bone marrow have worse prognosis than
patients with disseminated uPAR-negative cancer cells.27–29 A
signiﬁcant association between high expression levels of
uPAR in primary tumors and uPAR-positive disseminated
tumor cells was also reported.30 These observations suggest
that elevated expression of uPAR in tumors and particularly
in cancer cells may be an indication of more aggressive gas-
tric cancers. Therefore, uPAR expression in cancer cells may
represent an important prognostic marker for patients with
gastric cancer. In addition, studies in gastric cancer cell lines
have reported increased uPAR mRNA levels when neoplastic
cells are cocultured with H. pylori,31,32 suggesting that
H. pylori may induce the expression of uPAR in gastric mu-
cosa. This may link uPAR with early steps of gastric carcino-
genesis, which contributes to explain the association between
H. pylori and gastric cancer and the correlation observed
between the incidence rates of this malignancy and the prev-
alence of the bacterium.33
This study has been conducted to compare the expression
and presence of uPAR in gastric cancer cells in cases from
high- and low-risk countries (Costa Rica and Norway, respec-
tively) and to explore the possible connection between uPAR
expression in gastric mucosa and H. pylori infection.
Material and Methods
Tissue samples
Formalin-ﬁxed and parafﬁn-embedded gastric cancer tissue
(neoplastic and nonneoplastic) were obtained postoperatively
from 44 gastric cancer cases in 2 hospitals in Costa Rica
(Max Peralta Hospital and Rafael Angel Caldero´n Guardia
Hospital) and 23 cases from Bergen, Norway (Haukeland
University Hospital). Histopathological information was col-
lected from all the 67 cases. This histopathological classiﬁca-
tion was given according to the Laure´n Classiﬁcation System
(Norwegian cases) and Japanese Classiﬁcation System (Costa
Rican cases). For the purposes of this study, Costa Rican
cases were reclassiﬁed according to Laure´n Classiﬁcation Sys-
tem following established criteria given by the Japanese Gas-
tric Cancer Association.34 Thus, of the 44 Costa Rican cases,
27 were classiﬁed as intestinal subtype and 17 as diffuse sub-
type. Among the 23 Norwegian cases, 15 were intestinal sub-
type and 8 were diffuse subtype. According to the Interna-
tional Union Against Cancer (IUCC) criteria, the 44 Costa
Rican cases were staged as follows: 16 (36%) stage IA, 3 (7%)
stage IB, 5 (11%) stage II, 3 (7%) stage IIIA, 4 (9%) stage
IIIB, 7 (16%) stage IV and in 6 (14%) cases it was not known
(pN was missing on the records). Accordingly, among the 23
Norwegian cases, 0 had stage IA, 1 (4%) stage IB, 6 (26%)
stage II, 0 stage IIIA, 1 (4%) stage IIIB and 15 (66%) stage
IV. Survival data could not be obtained from the Costa Rican
cases, but they were available for the 23 Norwegian cases.
The study was approved by the respective Ethical and
Research Committees of each institution (Costa Rica: VI 742-
94-571, VI 742-99-340; Norway: REK 053228) and performed
in accordance with the World Medical Association Declara-
tion of Helsinki, 1996.
Antibodies
Afﬁnity puriﬁed monoclonal antibodies (clones R2 and R4)
and rabbit polyclonal antibodies (pAbs) against human uPAR
have been described previously.35,36 mAbs against cytokera-
tin-19 (clone RCK108), cytokeratins (clones AE1/AE3), CD68
(clone KP1), rabbit pAbs against H. pylori (code no. B0471),
FITC-conjugated goat anti-mouse IgG and nonimmune rab-
bit IgG were purchased from Dako (Glostrup, Denmark).
FITC-conjugated goat anti-rabbit IgG, Cy3-conjugated goat
anti-mouse and Cy3-conjugated goat anti-rabbit were
obtained from Jackson Immunoresearch (West Grove, PA).
Monoclonal antibody directed against trinitrophenyl hapten
(TNP, IgG1) was previously described.37
Immunoperoxidase staining
Three to four micrometer parafﬁn-embedded tissue sections
were deparafﬁnized with xylene and hydrated in gradual se-
ries of ethanol-water dilutions. For uPAR R2, uPAR pAb,
both cytokeratins (CKs), anti-H. pylori and anti-TNP, sec-
tions were pretreated with Proteinase-K (10 lg/mL) for 25
min at 37C. For R4 immunohistochemistry, sections were
heat-treated in a T/T Micromed microwave processor (Mile-
stone, Sorisol, Italy) at 98C for 15 min in target retrieval so-
lution (code no. S1699 pH 6.0; Dako). Endogenous peroxi-
dase activity was blocked by incubation in 1% hydrogen
peroxide solution for 15 min. The primary antibodies were
diluted in antibody diluent (Dako) and incubated for 2 hr in
Shandon racks (Thermo Shandon, Pittsburg, PA) at the fol-
lowing dilutions: uPAR R2 0.9 lg/mL, uPAR R4 5.1 lg/mL,
uPAR pAb 1.8 lg/mL, CKs 1:300, anti-H. pylori 1:150. Subse-
quently, the primary antibodies were detected with EnVision
reagent, either anti-mouse IgG or anti-rabbit IgG horseradish
peroxidase-conjugated polymers (Dako). The reactions were
visualized by incubating the sections with NovaRED (Vector
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Laboratories, Burlingame, CA) or DAB Chromogen (Dako)
(for H. pylori pAbs) according to manufacturer’s instructions
and counterstained with Mayer’s haematoxylin.
Negative controls
The sections were pretreated in the same way as previously
described for all the antibodies. The polyclonal anti-uPAR
was substituted with normal rabbit immunoglobulin (code
No. X903 Dako) incubated in an Ig concentration equivalent
to that used for the speciﬁc primary antibody. Monoclonal
antibodies R2 and R4 were substituted with anti-TNP mAb
incubated at the same concentrations as those for R2 and R4.
Immunoﬂuorescence staining
For the double immunoﬂuorescence analyses, sections were
initially processed as mentioned earlier for uPAR pAbs, using
proteinase-K pre-treatment. uPAR pAbs (2.4 lg/mL) were
diluted in Dako antibody diluent and incubated 2 hr at room
temperature, together with a mixture of mouse monoclonal
antibodies against CK-19 and CK AE1/AE3 (CKs, 1:300).
The uPAR pAb was detected with Cy3-conjugated goat anti-
rabbit IgG, 1:200 and the mixture of monoclonal antibodies
against CKs with FITC-conjugated goat anti-mouse IgG,
1:200. To carry out double staining for uPAR and H. pylori,
the sections were heat-treated by using target retrieval solu-
tion (code no. S1699 pH 6.0; Dako). The monoclonal anti-
uPAR R4 (5.1 lg/mL) was diluted in antibody diluent
(Dako) together with anti-H. Pylori pAbs (1:150) and incu-
bated on the tissue sections for 2 hr at room temperature.
The antibodies were subsequently detected with Cy3-conju-
gated goat-antimouse IgG, 1:200 and FITC-conjugated goat
anti-rabbit IgG, 1:200, respectively. After brief rinses with
TBS, the sections were mounted with Prolong Gold antifade
(Molecular Probes, Eugene, OR).
For the triple immunoﬂuorescence analyses, Zenon anti-
body-labelling technology (Molecular Probes, Eugene, OR)
was applied, following the manufacturer’s instructions.
Brieﬂy, sections were heat-treated with target retrieval solu-
tion (code no. S1699 pH 6.0; Dako) as described mentioned.
Anti-CD68 (clone KP1 and IgG1) was linked to Zenon 647
IgG1 according to the manufacturer’s instructions, complexed
anti-CD68 and mixed with uPAR pAbs (2.4 lg/mL) diluted
in antibody diluent (Dako). The mix of the 2 antibodies was
added to the sections and incubated 2 hr at room tempera-
ture. After washing with TBS, uPAR pAbs were detected with
Cy3-conjugated goat anti-rabbit (1:200). Subsequently, CKs
(clones AE1/AE3) was linked to Zenon 488 IgG1 according
to the manufacturer’s instructions and incubated on the tis-
sue sections overnight at 4C. Finally, tissue sections were
washed with TBS and mounted with Prolong Gold antifade
(Molecular Probes, Eugene, OR).
Confocal Microscopy
The double and triple stained sections were analyzed using a
confocal laser-scanning microscope, LSM 510 META (Carl
Zeiss, Jena, Germany) equipped with a 488 nm Argon laser,
a 543 nm HeNe1 laser and a 633nm HeNe2 laser. The
images were obtained using the lambda mode (pinhole diam-
eter 135 lm) collecting ﬂuorescent signals from 509 to
595 nm wavelength (double staining) or 509–691 nm wave-
length (triple staining). For separation of the speciﬁc ﬂuores-
cence signals, we ﬁrst obtained FITC, Cy3, Alexa ﬂuor 647
and erythrocyte autoﬂuorescence emission spectra from sin-
gle-ﬂuorophore stained sections. From double- and triple-la-
beled sections, the collected ﬂuorescence signal was separated
by the emission ﬁngerprinting using the above emission spec-
tra to separate the individual ﬂuorescence signals as
described.38 Nomarsky differential interference contrast
(phase image technique) was used to show the tissue struc-
tures revealed by refractive index inhomogeneities.
Scoring for the immunoperoxidase stainings
The sections stained for R2 mAb and uPAR pAbs were eval-
uated by 2 independent investigators. uPAR immunoreactiv-
ity in cancer cells was scored based on the estimated percent-
age of positive cells seen in the whole section. Thus, the
percentage of positive cancer cells were grouped into the fol-
lowing categories: 0, (no uPAR positive cancer cells detected);
1, less than 1% positively stained cancer cells (some few
observed at the invasive edges of the tumor); 2, between 1
and 5% positive cancer cells; 3, between 5 and 10% positive
cancer cells and 4, more than 10% positively stained cancer
cells (Fig. 2).
H. pylori immunoreactivity was scored based on the den-
sity of bacteria and the number of crypts containing bacteria
into the following categories: , no evidence of H. pylori on
the section; þ, less than 3 crypts with small clusters of bacte-
ria; þþ, either less than 3 crypts with dense clusters of bacte-
ria or more than 3 crypts with small clusters and þþþ, 3 or
more crypts with dense clusters of bacteria (Figs. 4h and 4i).
To assess the relation between uPAR expression in epithe-
lial cells and H. pylori infection, tissue sections from adjacent
normal nonneoplastic gastric mucosa stained for R2 mAb
were evaluated independently by 2 investigators. This evalua-
tion was blinded regarding the H. pylori status and was based
on the estimated percentage of crypts showing uPAR-positive
epithelial cells (Fig. 4c) as follows:0, 0–5% positive crypts;
1þ, 5–30% positive crypts; 2þ, 30–60% positive crypts and
3þ, more than 60% positive crypts.
Statistical analysis
v2 analysis was performed to evaluate the possible differences
regarding: the frequency of cases having uPAR-positive
cancer cells between Costa Rican and Norwegian cases, the
frequency of cases having uPAR-positive cancer cells in
intestinal versus diffuse subtypes, the H. pylori positivity
between the 2 countries and the association between uPAR
expression in gastric epithelial cells and H. pylori infection.
The association between uPAR immunoreactivity in cancer
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cells and UICC stage was assessed by v2 statistics of exact
probabilities. p ¼ 0.05 was considered statistically signiﬁcant
in all cases.
Results
uPAR expression in intestinal and diffuse
subtypes of gastric cancer
Immunoperoxidase staining for uPAR in both intestinal and
diffuse histological subtypes revealed uPAR expression in all
the 44 cases (Costa Rica). In gastric cancers of intestinal sub-
type, uPAR was mainly seen in the stroma along the invasive
front of the tumors (Figs. 1a and 1c) with the most intense
signal being observed in areas with abundant invasion of
neoplastic single cells (Figs. 1a and 1b). In contrast, in gastric
cancer of diffuse subtype the uPAR-positive cells were seen
both in the invasive front and in central areas of the tumors
as single cancer cells and/or small clusters of cancer cells
(Fig. 1d). The expression of uPAR in various cell types along
the invasive front in both intestinal and diffuse subtype was
histologically complex, but at the general level the uPAR-pos-
itive cells included cancer cells, macrophages and neutrophils
(Figs. 1a, 1c, and 1f). In some cases, positive ﬁbroblasts and
nerve bundles were also observed (not shown). In 7 cases
with intramucosal carcinoma, all of them intestinal subtype,
uPAR staining was seen in the adjacent stroma, suggesting
that uPAR is upregulated early during gastric cancer develop-
ment (Fig. 1e).
The speciﬁcity of the uPAR immunoreactivity was based
on the analysis of a series of positive and negative controls.
An identical uPAR staining pattern was obtained with 3
Figure 1. Immunoperoxidase staining for uPAR in gastric cancer. Parafﬁn sections from intestinal subtype (a–c, e–f) and invasive diffuse
subtype (d, g–i) were incubated with pAbs against uPAR(a, c, g), R2 mAb against uPAR (d–f, h), mAb against CK (b) and a mAb against TNP (i).
a–b and g–i represent adjacent sections. In (b), CK-positive neoplastic single cells (S), cell clusters (C) and glands (G) in an intestinal subtype
gastric cancer case are shown. In the gastric cancer of intestinal subtype, uPAR is focally upregulated in the stromal tissue at the invasive front
(a; St: stroma, Ca: cancer, c), while in the diffuse subtype the uPAR-positive cells are widespread within the tumor (d). The intramucosal
carcinoma with incipient gastric cancer cells (indicated by a star in e) is accompanied by uPAR expression in the adjacent stroma.
Macrophages and neutrophils located in the stromal area connected to the invasive front are the main producers of uPAR in gastric cancer (f;
St: stroma, Ca: cancer). An identical staining pattern is seen with pAb (g) and R2 mAb (h) against uPAR, while no speciﬁc staining is seen with
the mAb against TNP (i). Sections were counterstained with haematoxylin. Scale bars: 100 lm (a–b), 25 lm (c–d, f), 50 lm (e, g–i).
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different anti-uPAR antibodies (R2, R4 and pAbs) in 28 gas-
tric cancer cases (Figs. 1g and 1h). As negative controls, we
substituted R2 and R4 uPAR mAbs with a mAb against TNP
and the uPAR pAbs with normal rabbit immunoglobulin. No
speciﬁc staining was obtained with these 2 antibodies when
incubated at similar immunoglobulin concentrations as the
respective anti-uPAR antibody preparations (Fig. 1i).
uPAR is expressed in gastric cancer cells in both intestinal
and diffuse subtypes
Our immunoperoxidase staining suggested that uPAR-posi-
tive cancer cells are present in both intestinal (Figs. 2a–2d)
and diffuse subtype of gastric cancer (Figs. 2e–2i). To further
substantiate this observation, immunoﬂourescence analyses
for uPAR in combination with CKs and/or CD68 were per-
formed in a subset of 9 cases, from both histological sub-
types, with particularly complex uPAR expression pattern. In
intestinal subtype, uPAR was present in both CK-positive
cancer cells and in adjacent CD68-positive macrophages
(Figs. 3a–3c), whereas uPAR in diffuse subtype was predomi-
nantly seen in CK-positive cancer cells (Figs. 3d–3f).
uPAR is expressed by cancer cells in both Costa Rican
and Norwegian gastric cancers
Based on our uPAR immunoperoxidase staining, we ﬁrst
evaluated the frequency of uPAR-positive cancer cells in all
the 44 gastric cancer cases from Costa Rica. In 24 of the 44
cases (54%) uPAR-positive cancer cells were observed, with a
similar frequency in intestinal and diffuse subtypes (p ¼ 0.65;
v2 ¼ 0.21). No association between uPAR immunoreactivity
in cancer cells and tumor stage was demonstrated (p ¼ 0.54;
Table 1). Because gastric cancer incidence and mortality rates
markedly vary depending on geographical location,7 we then
compiled a series of 23 cases from the low risk country (Nor-
way) with a similar distribution of intestinal and diffuse sub-
type cases as compared to the Costa Rican series. We tested
whether the frequency of uPAR-positive cancer cells was sim-
ilar to that in the Costa Rican material (Table 1). In general,
Figure 2. uPAR immunoperoxidase staining for semiquantitative assessment of uPAR-positive gastric cancer cells. Parafﬁn sections from
intestinal subtype (a–d) and diffuse subtype (e–h) gastric carcinomas were processed for immunoperoxidase staining with pAbs against
uPAR and semiquantitatively evaluated for their presence of uPAR-positive cancer cells (see Material and methods). Examples of cases
scored as <1% uPAR-positive cancer cells (a, e), 1–5% uPAR-positive cancer cells (b, f), 5–10% uPAR-positive cancer cells (c, g), >10%
uPAR-positive cancer cells (d, h). Scale bar: 25 lm (a–h).
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uPAR immunoreactivity in the Norwegian cases was found
in all 23 cases, with a pattern of expression indistinguishable
to that observed in the cases from Costa Rica. In 13 of the
23 cases from Norway (56%), uPAR-positive cancer cells
were observed, with similar frequency of intestinal and dif-
fuse subtype cases showing uPAR-positive cancer cells (p ¼
0.67; v2 ¼ 0.18) and no signiﬁcant association between uPAR
immunoreactivity in cancer cells and tumor stage was dem-
onstrated (p ¼ 0.89; Table 1). Analysis of overall survival of
the Norwegian patients suggested that uPAR-positive cancer
cells could be a prognostic variable (Cox regression analysis,
Hazard ratio ¼ 1.6; 95% CI: 0.5–5) and although not signiﬁ-
cant, the sample size was very low. We found no statistically
signiﬁcant differences when we compared the frequency of
Costa Rican versus Norwegian cases of intestinal subtype gas-
tric cancers showing uPAR-positive cancer cells (p ¼ 0.93; v2
¼ 0.01) or of diffuse subtype gastric cancers with uPAR-posi-
tive cancer cells (p ¼ 0.86; v2 ¼ 0.03; Table 1). When the
category ‘‘less than 1% uPAR þ cancer cells’’ is not consid-
ered as positive (Table 1), the proportion of intestinal and
diffuse subtype cases showing uPAR-positive cancer cells
remain similar in both countries (p ¼ 0.89; v2 ¼ 0,02 Costa
Rica; p ¼ 0.26; v2 ¼ 1.25 Norway), and the frequency of
Costa Rican versus Norwegian intestinal (p ¼ 0.65; v2 ¼ 0.2)
and diffuse subtype gastric cancers with uPAR-positive can-
cer cells (p ¼ 0.48; v2 ¼ 0.49). Accordingly, no signiﬁcant
association between uPAR immunoreactivity in cancer cells
and tumor stage was demonstrated in any of the countries
(p¼ 0.98 Costa Rica; p ¼ 0.72 Norway).
H. pylori associates with the induction
of uPAR in gastric mucosa
Analysis of uPAR expression in non-neoplastic mucosa with
some degree of inﬂammation showed uPAR immunoreactiv-
ity in gastric epithelial cells located toward the gastric lumen
in the Costa Rican material (Figs. 4a and 4d). Because a pos-
sible relation between H. pylori and induction of uPAR
expression in gastric cancer cells has been suggested,30,32 we
Figure 3. Immunoﬂuorescence analyses for identiﬁcation of uPAR in cancer cells in gastric cancer lesions. Tissue sections from intestinal (a–
c) and diffuse (d–f) subtypes of gastric cancer were incubated with pAbs against uPAR together with mAbs against CKs (double staining in
d–f) or together with mAbs against CKs and mAb against CD68 (triple staining in a–c). For double immunoﬂuorescence analysis (d–f), the
pAbs against uPAR were detected with Cy3-conjugated goat anti-rabbit (red ﬂuorescence) and the mAbs against CKs with FITC-conjugated
goat anti-mouse (green ﬂuorescence). For triple immunoﬂuorescence analysis (a–c), uPAR pAbs were detected with Cy3-conjugated goat anti
rabbit (red ﬂuorescence) together with mAbs against CKs (green ﬂuorescence) and mAb against CD68 (blue ﬂuorescence) using Zenon
Antibody Labelling Technology. In gastric cancer tissue, uPAR-positive cancer cells are seen in both intestinal (a–c; white arrows) and diffuse
(d–f; white arrows) subtypes. Several CD68-positive macrophages located in the invasive area in close proximity to cancer cells were
strongly uPAR-positive (a–c; blue arrows). Nomarsky DIC imaging technique was used in f. Scale bar: 10 lm (a-f).
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explored the possibility that uPAR is upregulated in gastric
epithelium as a consequence of H. pylori infection. Samples
from nonneoplastic mucosa were stained for H. pylori. Im-
munoperoxidase staining showed H.pylori in 77% (34 of 44)
of the Costa Rican and 30% (7 of 23) of the Norwegian cases
(p ¼ 0.00021; v2 ¼ 13.71). H. pylori clusters were observed
at the luminal space of the crypts, in direct contact with epi-
thelial cells of the surface and deeper areas of the crypts, and
inside some of the mucosal glands (Figs. 4e and 4f), with the
highest density of bacteria in foci of gastritis-affected mucosa
(Fig. 4f). Immunoperoxidase staining for uPAR in adjacent
tissue sections of non-neoplastic mucosa from the 23 Norwe-
gian cases (Table 2), showed expression of uPAR in surface
epithelial cells located toward the gastric lumen, similar to
our observation in the Costa Rican material (Figs. 4a–4d).
The presence of uPAR on surface epithelial cells was signiﬁ-
cantly associated with the presence of H. pylori (p ¼ 0.033;
v2 ¼ 4.54). Indeed, double immunoﬂuorescence analysis for
uPAR and H. pylori in tissue sections of non-neoplastic tissue
adjacent to the neoplastic growth from 8 of the patients with
gastric cancer from Costa Rica (5 H. pylori-positive and 3
H. pylori-negative), showed intense uPAR immunoreactivity
in surface epithelial cells located at the luminal edge of the
crypts that were in direct contact with bacteria in the
H. pylori-positive patients (Figs. 4h and 4i). In contrast, the
H. pylori-negative cases showed no or weak uPAR expression
in epithelial cells at similar location (not shown).
Discussion
In this study, we show that uPAR is expressed in a part of can-
cer cells in approximately 50% of all gastric cancers in both
high- and low-risk countries. Our ﬁndings suggest the further
evaluation of uPAR as a potential immunohistochemical pa-
rameter, which, based on the prevalence of uPAR-positive can-
cer cells in the tumor, may provide prognostic information
about the patient. Our observations are based on immunohis-
tochemical analyses of 2 uPAR mAbs (R2 and R4) directed
against 2 different domains on uPAR, and a preparation of af-
ﬁnity puriﬁed polyclonal antibodies against uPAR.35,36 The 3
different antibody preparations identiﬁed uPAR on gastric can-
cer cells and stromal cells to the same extent, while a mAb
directed against the TNP hapten or non-immune rabbit IgG
showed no speciﬁc staining. We therefore conclude that the
uPAR staining observed represent the genuine uPAR protein.
The assumption that uPAR-positive gastric cancer cells
are of particular aggressive character is based on analyses of
Table 1. uPAR immunoreactivity of cancer cells in cases from costa rica and norway according to
histological subtypes and tumor stage
Costa Rica Norway Total
Total number of cases 44 23 67
Intestinal subtype 27 15 42
Diffuse subtype 17 8 25
Cases with uPAR þ cancer cells 24 13 37
Intestinal subtype cases with uPAR þ cancer cells 14 8 22
<1% uPAR þ cancer cells 5 4 9
1–5% uPAR þ cancer cells 2 3 5
5–10% uPAR þ cancer cells 3 0 3
>10% uPAR þ cancer cells 4 1 5
Diffuse subtype cases with uPAR þ cancer cells 10 5 15
<1% uPAR þ cancer cells 4 1 5
1–5% uPAR þ cancer cells 0 2 2
5–10% uPAR þ cancer cells 3 0 3
>10%uPAR þ cancer cells 3 2 5
Cases with uPAR þ cells according to tumor stage1
IA 6 0 6
IB 1 1 2
II 3 3 6
IIIA 3 0 3
IIIB 2 0 2
IV 4 9 13
Unknown2 5 0 5
1The total distribution of cases according to tumor stage is given in the Material and methods section.
2Not possible to classify because pN was missing on the records.
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micro-metastatic cells identiﬁed in bone marrow aspirates
from patients with gastric cancer,27 and its signiﬁcant associ-
ation with survival.29 We found uPAR-positive gastric cancer
cells with the same frequency in intestinal and diffuse sub-
types. In their study, Heiss et al.29 found no signiﬁcant corre-
lation between the presence of uPAR-positive micro-meta-
static cells in bone marrow aspirates and Laure´n’s
classiﬁcation, meaning that these cells were observed with
similar frequency in both intestinal and diffuse subtype.
Thus, an accurate determination of the prevalence of uPAR-
positive gastric cancer cells by immunohistochemistry could
be of fundamental importance owing to its potential prognos-
tic signiﬁcance and the repercussions that this may have for
Figure 4. Immunohistochemical analyses of uPAR and H. pylori in non-neoplastic gastric mucosa. Sections from samples with gastric
mucosa adjacent to the neoplastic lesion were processed for immunoperoxidase staining for uPAR (a–d), H. pylori (e–f) or for
immunoﬂuorescence analysis (g–h) using pAbs against uPAR, pAbs against H. pylori and uPAR mAb R4 together with H. pylori pAbs,
respectively. In normal-like mucosa (a), uPAR is expressed by epithelial cells (E) located at the apical part of gastric mucosa, scattered
neutrophils and some inﬂammatory cells in the lamina propia. In gastritis-affected mucosa, uPAR is seen in neutrophils (N) (b; star, d) and
epithelial cells (E) (b–c) more evidently than in normal-like foci. Scattered uPAR-positive macrophage-like cells (M) can be observed in
gastritis-affected mucosa (d). H. pylori clusters (red stars) can be observed at the luminal side in some of the crypts along the gastric
mucosa (e) with the highest density in gastritis-affected mucosa (f). In the double immunoﬂuorescence analysis R4 mAb against uPAR
together with pAbs against H. pylori (double staining in g–h) were detected with Cy3-conjugated goat anti-mouse (red ﬂuorescence) and
FITC-conjugated goat anti rabbit (green ﬂuorescence), respectively. Intense uPAR immunoreactivivity is seen in epithelial cells in direct
contact with H. pylori bacteria (g–h; white arrows). Scale bars: 100 lm (a–b), 50 lm (c–d), 12 lm (e–f), 20 lm (g–h).
Table 2. uPAR immunoreactivity in apical epithelial cells in relation
to the H. pylori status in non-neoplastic tissue sections from norway
uPAR scoring
0 11 21 31 Total
H. pylori positive 2 1 3 1 7
H. pylori negative 14 1 1 0 16
C
an
ce
r
C
el
l
B
io
lo
gy
412 Expression of uPA receptor in gastric cancer
Int. J. Cancer: 126, 405–415 (2010) VC 2009 UICC
the treatment and survival of patients with gastric cancer.
We are already working on a larger and independent study
to evaluate the usefulness of uPAR immunoreactivity of gas-
tric cancer cells as prognostic variable.
In this study, we found uPAR-positive cancer cells in more
than 50 percent of the cases with similar frequency in intesti-
nal and diffuse subtypes of gastric cancer. In contrast, Migita
et al.15 observed uPAR-positive cancer cells in only 16 cases
of 78 intestinal subtype gastric cancers and in none of diffuse
subtype gastric cancers. A methodological difference in the
immunohistochemical staining of uPAR between Migita
et al.15 and ours is the proteolytic pre-digestion step. Migita
et al.15 used trypsin, whereas we used proteinase-K. Epitope
demasking is a crucial step for most immunohistochemical
analyses. We have observed that the efﬁciency of the proteo-
lytic predigestion strongly inﬂuence the intensity of uPAR im-
munoreactivity (Alpı´zar-Alpı´zar and Nielsen, unpublished
observations). It cannot be excluded, however, that geographi-
cal differences could explain the differences (see also below).
Kawasaki et al.19 used in situ hybridization and found uPAR
mRNA expression in cancer cells in both intestinal and dif-
fuse subtypes (5 of 33 cases and 14 of 58 cases, respectively).
The strongest contribution to uPAR immunoreactivity in
the gastric cancer samples was in general the stromal cell pop-
ulation, particularly the inﬂammatory cells, macrophages and
neutrophils. These cell populations are generally found to be
uPAR-positive in a number of tissue types.14,39 Immunohisto-
chemical analysis of uPAR has therefore appeared to be quite
complex; not only in gastric cancer but also in breast, oral
and colon cancer, where double immunoﬂuorescence analyses
have been crucial for a sufﬁcient discrimination of the differ-
ent uPAR-positive cell populations.12,13,16 uPAR-positive can-
cer cells are found in different types of carcinomas with vary-
ing occurrence including colon, breast and oral cancer.12,13,16
In colon cancer, the uPAR-positive cancer cells are located at
the invasive front13,40 as they also are in the gastric cancers of
intestinal subtype (15 and this article), suggesting similar inva-
sion mechanisms in these 2 gastrointestinal adenocarcinomas.
Expression of uPAR in both cancer cells and stromal cells
contribute to the total level of uPAR in the cancer tissue.
However, it is currently unknown to which extent uPAR
derived from the different cell populations contribute to the
prognostic signiﬁcance of uPAR and the uPAR degradation
products that can be measured in blood and tissue extracts.41
It is believed that uPAR expression on cells facilitate cell
migration by interacting with extracellular matrix compo-
nents like vitronectin,42,43 or with other cell surface associ-
ated proteins, like integrins.44 Therefore, expression of uPAR
on cancer cells is likely to enhance its potential to invade and
metastasize. In a metastasis model, transgene overexpression
of uPAR in tumor cells confers enhanced proliferative and
metastatic potential dependent on the interaction of uPAR
with integrins and ﬁbronectin.45–50 These observations might
explain the correlation found between the presence of uPAR-
positive micro-metastatic cancer cells in the bone marrow
and poor prognosis in patients with gastric cancer.29,51
Hence, the clinical relevance of uPAR expression in neoplas-
tic cells of gastric cancer may be based on its proinvasive,
prometastastatic and proliferative properties.
Gastric cancer incidence presents important variations
according to geographical regions.1 The factors explaining
these variations remain unknown so far given the complexity
and multifactorial nature of the disease. These different inci-
dence rates are likely to be explained by ethnical, environ-
mental, cultural and socioeconomic aspects. For example,
studies assessing the association between genetic polymor-
phisms of pro and anti-inﬂammatory cytokines and gastric
cancer have shown different results depending on geographi-
cal regions.52–54 Likewise, differences between H. pylori
strains among geographical regions correlate well with the
distribution of the gastric cancer incidence.33 This suggests
that when studying aspects potentially related with gastric
cancer development and progression, geographical regions
are important to take into account. In this study, we deter-
mined the expression of uPAR in cancer cells, in gastric can-
cer tissue obtained from a country with one of the highest
gastric cancer incidence rates worldwide (Costa Rica) and
one with low incidence rate (Norway).7 We did however ﬁnd
similar frequency of uPAR-positive cancer cells in Costa
Rican and Norwegian gastric cancer cases, suggesting that the
expression of uPAR and its potential role in gastric cancer
development and progression is independent of geographical,
ethnical or environmental differences. Though, it cannot be
excluded that gastric cancer developing in other geographical
regions could present different uPAR expression patterns.
Another important ﬁnding in this study was the intense
uPAR immunoreactivity in epithelial cells located at the
luminal edge of the non-neoplastic mucosa. Epithelial cells at
this location can, eventually, be in direct contact with H.
pylori bacteria, and this organism is associated with several
responses in the gastric mucosa.55,56 A semiquantitative anal-
ysis of H. pylori-positive cases and the presence of uPAR-
positive surface epithelium revealed a signiﬁcant association,
and indeed we found H. pylori clusters in close proximity to
uPAR-positive surface epithelium by double immunoﬂuores-
cence analysis. In vitro studies have shown increased levels of
both uPAR mRNA and uPAR antigen when gastric cancer
cell lines are challenged with H. pylori,32,57 and when cocul-
tured with H. pylori cagA-positive versus negative strains.31,58
These observations taken together suggest that H. pylori may
be directly involved in the induction of uPAR in the gastric
mucosa. It is tempting to speculate that H. pylori can stimu-
late the expression of uPAR in epithelial cells, which under
certain circumstances could potentiate the development of
gastric pathological conditions that leads to gastric neoplasia.
The ﬁndings in a mouse model where simultaneous trans-
gene overexpression of uPAR and uPA in mouse skin confer
a pathological epidermal phenotype59 and the enhanced pro-
liferation potential of uPAR-overexpressing transgenic cell
lines,45–50 support this idea. The ﬁnal outcome may, however,
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result from the interaction of uPAR with other molecules in
the mucosal microenvironment including uPA, extracellular
matrix proteins and mediators of inﬂammation released in
response to H. pylori infection. Hence, the possible connec-
tion between H. pylori and uPAR and its potential implica-
tions in gastric cancer development and progression need to
be further explored. These ﬁndings raise new and exciting
questions regarding the role of H. pylori and uPAR in the de-
velopment of gastric cancer, including elucidation of the role
of the various H. pylori virulence factors in the induction of
uPAR and the potential prognostic value of uPAR in gastric
cancer.
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